Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
   
Ask the Experts About

Choosing Your MedsChoosing Your Meds
           
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


which one to start with
Sep 6, 2004

Dear doctor, in terms of less long term drug toxicity and less likely to develop liopdystrphy what is your corrunt favorit conmbination theraphy for who is on the first line treatment no any drug resistance with CD350 and vL 60000: which one is your favourit one to start with :

1.Sustiva plus either Truvada (Viread + Emtriva) or Epzicom (Ziagen + Epivir).

or combivir + sustiva

or viread, + epivire + sustiva

plsease i need your oppinion on this thank you

Response from Dr. Pierone

In terms of tolerability and long term risk of lipodystrophy the combination of Viread with either Epivir or Emtriva has the most favorable profile. Truvada (Viread and Emtriva) is available and permits a lower pill burden (2 pills once daily when used with Sustiva) and is my favorite for first-line nucleoside use.



Previous
SN 1212 in development
Next
RE: Delines inCD4 with Videx (posted 9/5/04)

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement